Beneficial Effects of Ozone Therapy on Oxidative Stress, Cardiac Functions and Clinical Findings in Patients with Heart Failure Reduced Ejection Fraction
Özet
The aim of study was to determine the effects of ozone therapy on the oxidative stress, cardiac functions and clinical findings in patients with heart failure reduced ejection fraction (HFrEF). A total of 40 patients with New York Heart Association 2 and 3 HF with left ventricular ejection fraction (LVEF) <35%, and 40 subjects without HF as control group were included in the study. Patients with HFrEF were given additional ozone therapy of major and minor administrations along with conventional HF treatment for 5 weeks. Before and after ozone therapy, left ventricular end-systolic and end-diastolic volumes (LVESV, LVEDV) and the 6 minute walk distance (6MWD) and blood levels of the superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GSHPx), malondialdehyde (MDA), nitric oxide (NO) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Ozone therapy significantly reduced the serum levels of NO and MDA (p < 0.001, respectively) and significantly increased the levels of SOD, CAT, GSH and GSHPx (p < 0.001, respectively). LVEDV and LVESV were found to be significantly reduced; however, LVEF was not found to be significantly increased (p = 0.567). As the biochemical improvement marker of HF, NT-proBNP was significantly reduced (p < 0.001). The clinical HF improvement marker of 6 minute walk distance was also modestly increased (p < 0.001). Ozone therapy might be beneficial in terms of activating antioxidant system and merit further therapeutic potential to conventional HF treatment in patients with HFrEF. © 2017, Springer Science+Business Media New York.
Anahtar Kelimeler
Tam Kayıt
| Alan | Değer | Dil |
|---|---|---|
| dc.contributor.author | Buyuklu, Mutlu | |
| dc.contributor.author | Kandemir, Fatih Mehmet | |
| dc.contributor.author | Set, Turan | |
| dc.contributor.author | Bakırcı, Eftal Murat | |
| dc.contributor.author | Degirmenci, Husnu | |
| dc.contributor.author | Hamur, Hikmet | |
| dc.contributor.author | Topal, Ergun | |
| dc.contributor.author | Kucukler, Sefa | |
| dc.contributor.author | Turkmen, Kultigin | |
| dc.date.accessioned | 2026-10-18T20:29:21.088120184Z | |
| dc.date.available | 2026-10-18T20:29:21.088120184Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | The aim of study was to determine the effects of ozone therapy on the oxidative stress, cardiac functions and clinical findings in patients with heart failure reduced ejection fraction (HFrEF). A total of 40 patients with New York Heart Association 2 and 3 HF with left ventricular ejection fraction (LVEF) <35%, and 40 subjects without HF as control group were included in the study. Patients with HFrEF were given additional ozone therapy of major and minor administrations along with conventional HF treatment for 5 weeks. Before and after ozone therapy, left ventricular end-systolic and end-diastolic volumes (LVESV, LVEDV) and the 6 minute walk distance (6MWD) and blood levels of the superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GSHPx), malondialdehyde (MDA), nitric oxide (NO) and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured. Ozone therapy significantly reduced the serum levels of NO and MDA (p < 0.001, respectively) and significantly increased the levels of SOD, CAT, GSH and GSHPx (p < 0.001, respectively). LVEDV and LVESV were found to be significantly reduced; however, LVEF was not found to be significantly increased (p = 0.567). As the biochemical improvement marker of HF, NT-proBNP was significantly reduced (p < 0.001). The clinical HF improvement marker of 6 minute walk distance was also modestly increased (p < 0.001). Ozone therapy might be beneficial in terms of activating antioxidant system and merit further therapeutic potential to conventional HF treatment in patients with HFrEF. © 2017, Springer Science+Business Media New York. | |
| dc.description.sponsorship | Funding This study was supported by the Scientific Research Fund of Erzincan University. | |
| dc.identifier.doi | 10.1007/s12012-017-9400-8 | |
| dc.identifier.eissn | 1559-0259 | |
| dc.identifier.endpage | 433 | |
| dc.identifier.issn | 1530-7905 | |
| dc.identifier.issue | 4 | |
| dc.identifier.pmid | 28097518 | |
| dc.identifier.scopus | 2-s2.0-85009822924 | |
| dc.identifier.startpage | 426 | |
| dc.identifier.uri | https://rdlopen.rawdatalibrary.net/r/ebyu/14540 | |
| dc.identifier.volume | 17 | |
| dc.identifier.wos | WOS:000411104600006 | |
| dc.language.iso | en | |
| dc.publisher | Humana Press Inc. | |
| dc.relation.ispartof | Cardiovascular Toxicology | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | Antioxidant system | |
| dc.subject | Heart failure | |
| dc.subject | Oxidative stress | |
| dc.subject | Ozone therapy | |
| dc.subject | Aged | |
| dc.subject | Cohort Studies | |
| dc.subject | Female | |
| dc.subject | Humans | |
| dc.subject | Infusions, Intravenous | |
| dc.subject | Male | |
| dc.subject | Middle Aged | |
| dc.subject | Ozone | |
| dc.subject | Stroke Volume | |
| dc.subject | Treatment Outcome | |
| dc.subject | Ventricular Dysfunction, Left | |
| dc.subject | amino terminal pro brain natriuretic peptide | |
| dc.subject | catalase | |
| dc.subject | glutathione | |
| dc.subject | glutathione peroxidase | |
| dc.subject | malonaldehyde | |
| dc.subject | nitric oxide | |
| dc.subject | superoxide dismutase | |
| dc.subject | adult | |
| dc.subject | Article | |
| dc.subject | clinical article | |
| dc.subject | controlled study | |
| dc.subject | heart failure with reduced ejection fraction | |
| dc.subject | heart left ventricle ejection fraction | |
| dc.subject | heart left ventricle enddiastolic volume | |
| dc.subject | heart left ventricle endsystolic volume | |
| dc.title | Beneficial Effects of Ozone Therapy on Oxidative Stress, Cardiac Functions and Clinical Findings in Patients with Heart Failure Reduced Ejection Fraction | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| rdl.citation.scopus | 24 | |
| rdl.citation.wos | 22 | |
| rdl.department | Department of Cardiology, Faculty of Medicine, Erzincan University, 24500, Erzincan, Turkey. mutlubuyuklu@gmail.com. | Department of Cardiology, Faculty of Medicine, Erzincan University, 24500, Erzincan, Turkey. | |
| rdl.source.index | SCOPUS | |
| rdl.source.index | WOS | |
| rdl.source.index | PUBMED | |
| rdl.wos.index | Science Citation Index Expanded (SCI-EXPANDED) |
